Get the Stockscreener App
26.76
1.65%
-0.45
Surmodics Inc stock is traded at $26.76, with a volume of 37,501.
It is down -1.65% in the last 24 hours and down -5.27% over the past month.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
See More
Previous Close:
$27.21
Open:
$27.08
24h Volume:
37,501
Relative Volume:
0.32
Market Cap:
$395.23M
Revenue:
$138.20M
Net Income/Loss:
$5.52M
P/E Ratio:
70.42
EPS:
0.38
Net Cash Flow:
$9.86M
1W Performance:
-3.18%
1M Performance:
-5.27%
6M Performance:
-30.42%
1Y Performance:
-17.20%
1-Day Range:
$26.70
$27.37
1-Week Range:
$26.60
$28.10
52-Week Range:
$26.00
$42.44
Surmodics Inc Stock (SRDX) Company Profile
Name
Surmodics Inc
Sector
Industry
Phone
(952) 500-7000
Address
9924 W 74TH ST, EDEN PRAIRIE, MN
Compare SRDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRDX
Surmodics Inc
|
26.76 | 395.23M | 138.20M | 5.52M | 9.86M | 0.38 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Upgrade | Lake Street | Hold → Buy |
| Jun-13-23 | Upgrade | Needham | Hold → Buy |
| Feb-13-23 | Downgrade | Needham | Buy → Hold |
| Jul-23-20 | Upgrade | Needham | Hold → Buy |
| Dec-11-19 | Downgrade | Needham | Buy → Hold |
| Nov-01-19 | Downgrade | Lake Street | Buy → Hold |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Lake Street | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Feb-21-19 | Reiterated | Needham | Buy |
| May-16-18 | Reiterated | Needham | Buy |
| Mar-01-18 | Upgrade | Sidoti | Neutral → Buy |
| Feb-28-18 | Reiterated | Lake Street | Buy |
| Feb-28-18 | Initiated | Needham | Buy |
| Jul-14-17 | Initiated | Lake Street | Buy |
| Nov-21-16 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Oct-06-16 | Downgrade | Sidoti | Buy → Neutral |
| May-03-16 | Reiterated | Barrington Research | Outperform |
| Aug-06-15 | Reiterated | Barrington Research | Outperform |
| Mar-27-15 | Initiated | Dougherty & Company | Buy |
| Feb-25-14 | Initiated | Laidlaw | Buy |
| Aug-01-13 | Upgrade | Feltl & Co. | Buy → Strong Buy |
| Nov-12-12 | Reiterated | Barrington Research | Outperform |
View All
Surmodics Inc Stock (SRDX) Latest News
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results - ADVFN
Equities Analysts Issue Forecasts for Surmodics Q2 Earnings - Defense World
Legal & General Group Plc Buys 880 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Are Options Traders Betting on a Big Move in Surmodics Stock? - Yahoo Finance
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts - Yahoo Finance
SurModics: Fiscal Q2 Earnings Snapshot - New Haven Register
Surmodics Reports Q2 2025 Results Amid Acquisition Challenges - TipRanks
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
SurModics stock touches 52-week low at $26.21 amid market shifts - Investing.com
Surmodics (SRDX) Projects Declining Revenue for Fiscal 2025 | SR - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance - BioSpace
Surmodics (SRDX) Projects Declining Revenue for Fiscal 2025 | SRDX Stock News - GuruFocus
Surmodics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Surmodics (SRDX) Reports Lower Than Expected Q2 Revenue Amid Ant - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial R - GuruFocus
SURMODICS INC SEC 10-Q Report - TradingView
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance | SRDX Stock News - GuruFocus
Surmodics Reports Second Quarter Fiscal 2025 Financial Results - TradingView
A Look at Surmodics's Upcoming Earnings Report - Nasdaq
How To Trade (SRDX) - news.stocktradersdaily.com
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 - 01net
Surmodics to Report Second Quarter of Fiscal 2025 Financial Resu - GuruFocus
FTC Expands Lawsuit Against GTCR Over Surmodics Acquisition - MSN
Surmodics' SurVeil DCB Matches IN.PACT Admiral In Efficacy With Lower Drug Dose In Global Trial - Nasdaq
Surmodics (SRDX) Publishes Promising Clinical Trial Results for SurVeil DCB | SRDX Stock News - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
Illinois, Minnesota join FTC challenge against $627M Surmodics buyout - MedTech Dive
Minnesota AG Ellison joins federal lawsuit to stop merger of companies that make medical device coatings - KIMT
Illinois joins FTC suit to block GTCR’s takeover of Surmodics - Crain's Chicago Business
AG Ellison Joins Suit to Block Surmodics Acquisition - Twin Cities Business
Corebridge Financial Inc. Lowers Stock Position in Surmodics, Inc. (NASDAQ:SRDX) - Defense World
(SRDX) Long Term Investment Analysis - news.stocktradersdaily.com
Surmodics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal By Investing.com - Investing.com South Africa
Surmodics launches Pounce XL thrombectomy system - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal - Investing.com Australia
Revolutionary Blood Clot Treatment: Pounce XL Shows 80% Success Rate in Just 20 Minutes - Stock Titan
Gardner Lewis Asset Management L P Raises Position in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Learn to Evaluate (SRDX) using the Charts - news.stocktradersdaily.com
PE Firm Hits Back Against Medical Device Coating Challenge - Law360
FTC Challenges Medical Device Coatings Deal - Medical Product Outsourcing
Zacks Research Decreases Earnings Estimates for Surmodics - Defense World
Bank of New York Mellon Corp Sells 2,966 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Surmodics Inc Stock (SRDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):